April 2019 and Sep 2018
DEVELOPMENT OF NOVEL METFORMIN ANALOG FOR TREATMENT OF PARKINSON'S DISEASE (3R43NS108852-01S1 and 1R43NS108852-01)
Mitochondrial defects have been implicated in the pathogenesis of Parkinson's disease, but no treatment is currently available to improve the efficiency of dysfunctional mitochondria in PD. The main goal of this proposal is to determine the drug-like properties of MitoMet with favorable PK/PD profile for further development of this class of compound in preclinical animal models. It is anticipated our unique mitochondrial-targeted strategy will ultimately lead to the development of better therapeutic agents for the treatment of PD.
PRECLINICAL EVALUATION OF THE ANTI-NEUROINFLAMMATORY PROPERTIES AND PHARMACOKINETIC PROFILE OF A NOVEL FYN KINASE INHIBITORS (1R43NS110129-01)
Existing therapies to treat neurodegenerative diseases, such as Parkinson's disease (PD), focus mainly on treating symptoms rather than halting disease progression. Recent mechanistic studies indicate that Fyn kinase activation contributes to neurodegenerative processes in PD. Thus, in this proof-of-concept study, we will validate tri-heterocyclic small-molecule inhibitors of Fyn kinase as novel anti-neuroinflammatory agents for treating neurodegenerative disorders.
CALL US AT (515) 598-7654
CALL US at (515) 598-7654
Copyright © PK Biosciences Corporation. All rights reserved